Drugs / Sorivudine

Trials 3 · a red edge is where a trial was stopped

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT00652184 Mar 2008 → Jun 2009 herpes zoster, postherpetic neuralgia aRigen Pharmaceuticals, Inc. Unknown No outcome recorded
Phase 2 NCT00000953 ? → Sep 1996 HIV infectious disease, chickenpox National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00002358 HIV infectious disease, chickenpox Bristol-Myers Squibb Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Sorivudine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002358
2

NCT00652184

NCT00000953

Known as Bravavir ChEMBL registry synonym — accepted as the source's own label CHEMBL70046
Known as brovavir “oral sorivudine (brovavir)” NCT00000953
Known as BV-araU “To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.” NCT00002358
Known as SO 32,756 ChEMBL registry synonym — accepted as the source's own label CHEMBL70046
Known as Sorivudina ChEMBL registry synonym — accepted as the source's own label CHEMBL70046
Known as SQ 32,756 ChEMBL registry synonym — accepted as the source's own label CHEMBL70046
Known as YN-72 ChEMBL registry synonym — accepted as the source's own label CHEMBL70046
Modality Small molecule CHEMBL70046
Route Oral oral sorivudine (brovavir) and oral acyclovir” NCT00000953